The world of medicine is shifting from the traditional “one size fits all” approach to one where the genetic profile of patients is used to make the most effective clinical decisions for individual patients – a concept known as Personalized Medicine.
Personalized Medicine is a new important driver for the polymerase market. Personalized Medicine tries to tailor medical diagnostics and treatments to the individual characteristics of the patients, i.e., their genetic repertoire.
Automated systems for sequencing DNA or spot-checking for genetic variation at low costs are essential to progress in both research and clinical applications, and this is pushing forward the need for new polymerases adapted to the so called Next Generation Sequencing equipments.
In particular, SYGNIS’ polymerases enable a wide range of applications for DNA amplification, repair, sequencing, detection and modification of genetic targets of clinical value. The company is thus ideally suited to play a major part in the global effort to discover the genetic markers of disease, and their cost effective detection, in individual patients to deliver optimized treatments.
SYGNIS at a glance
SYGNIS is a German-Spanish stocklisted company devoted to the development of novel, superior tools for molecular biology that play key roles in changing the way genomic and proteomic research is done today. Demand for such tools is high in the fast-growing DNA and protein analysis markets.
SYGNIS has developed a well balanced product portfolio based on proprietary technologies:
- TruePrime™, a new product line based on PrimPol technology: TruePrime™ is the brand name of a series of kits dedicated to the amplification of various DNA or RNA species for a multitude of applications. TruePrime™ stands for a revolutionary change in the way DNA or RNA is amplified. While the current gold standard MDA (multiple displacement amplification) needs short pieces of DNA (“oligonucleotides”) to start off the amplification, TruePrime™ does not need any synthetic random primers. The company launched three proprietary kits based on this technology during 2015. The first one was intended for Whole Genome Amplification from single cells, the second one for Whole Genome Amplification of regular DNA and the third one for Rolling Circle Amplification of circular DNAs.
- SunScript™, a new product line based on a new RT (retrotranscriptase) technology: SunScript™ is the brand name of a series of kits based on novel proprietary engineered reverse transcriptase (RT) which today is one of the most thermostable and fastest enzyme commercially available in the market. RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA.
- SensiPhi®/QualiPhi, a novel DNA polymerase: SensiPhi® (formerly QualiPhi®) is a superior version of Phi29 DNA polymerase used for amplifying very small amounts of DNA. This is a key entry point needed to make samples accessible for downstream analyses such as sequencing or hybridization techniques and used in areas such as genetic counseling, pathology, forensics, and research. This DNA polymerase was licensed to QIAGEN in 2012. During 2015 Qiagen has launched several kits based on SensiPhi™.
- Double Switch, a new technology for the detection of interactions between proteins: During 2015, SYGNIS announced that it has signed a licence agreement for the Double Switch technology with Thermo Fisher Scientific, an American biotech company and one of the key leaders in the biotech sector. The licence agreement is based on SYGNIS’ proprietary Double Switch technology for the qualitative and quantitative detection of the interactions of two proteins. The agreement signed with Systasy last year was also based on some of the Double Switch patents.